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Epilepsy remains one of the leading public health problems that affects about 50 million people 
worldwide, thus stressing the need for new anticonvulsant drug. This study was designed to evaluate the 
anticonvulsant activity against Penty lenetetrazole induced–convulsion in mice. Plants were extracted by 
maceration with water or organic solvents. The extracts were tested against PTZ-induced convulsion by 
measuring onset seizure, clonic seizure onset, convulsion duration, death time and percentage of protecti n. A. 
cordifolia leaf extract protected all animals from death at 1000 mg/kg. A. muricata stem extract delayed 
seizures at 200 and 400 mg/kg, while the onset of tonicoclonic (TC) seizures was significantly delayed at the 
highest doses tested for the seed extract (800 mg/kg). Stem and leaf extracts of A. senegalensis ignificantly 
delayed seizure onset at all doses. D. adescendes extract significantly protected mice from death. F. thonningii 
leaf extract at the smallest dose tested (200 mg/kg), si nificantly delayed the seizure onset and the occurrence 
of TC convulsions. Bark extract of V. doniana significantly delayed the seizure onset at all doses tested. The 
results obtained corroborate with the traditional cl ims that these plants can be a valuable source of new 
anticonvulsant compounds. 
© 2014 International Formulae Group. All rights reserved. 
  




Epilepsy is one of the most common 
neurological disorders with no age, social, 
sexual or geographical boundaries (WHO, 
2001). It affects about 50 million people 
worldwide (Moshi et al., 2005). This epilepsy 
prevalence far exceeds those in developing 
countries (Baskind and Birbeck, 2005). In 
Cameroon, epilepsy prevalence reaches 6% in 
some endemic areas (Njamnshi et al., 2009a) 
such as Badissa in the Center region 
(Njamnshi et al., 2009b). In most societies, 
epilepsy is regarded as possession by evil 
spirits, and is seen as a highly contagious and 
shameful disease (Moshi et al., 2005). This 
stigma has long been recognized as a major 
burden to people with epilepsy and their 
families especially in sub-Saharan Africa 
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where the combination of poverty, social role 
expectations, limited medical care, and 
traditional beliefs coalesce to severely limit 
their live span (Baskind and Birbeck, 2005). 
In the developed countries, where drugs 
are easily available, epilepsy responds to 
treatment in up to 70% of the patients 
(Ilodigwe et al., 2010). However, in 
developing countries, 75% of people with 
epilepsy do not receive the appropriate 
treatment (WHO, 2001) and their epilepsy 
remains uncontrolled, rendering the patients 
unproductive in all spheres of life. In the 
scarcity of such drugs, they mainly rely on 
traditional medicines as the only mains of 
control in both rural and urban areas (Moshi et 
al., 2005) of these countries. In fact, 80% of 
the population relies on traditional medicines 
or folk remedies for their primary health care 
need (Hedge et al., 2009). In Cameroon, 
traditional indigenous medicine still plays an 
important role in epilepsy management with 
up to 25% of epileptic patients relying on 
traditional treatment (Njamnshi et al., 2009c). 
Medicinal plants are believed to be an 
important source of new drugs and lead 
compounds with potential therapeutic effects. 
The inclusion of those with proven safety and 
efficacy in the healthcare programs of 
developing countries is encouraged by the 
WHO because of the great potential they 
possess in combating various diseases 
(Chindo et al., 2009). Several plants used for 
the treatment of epilepsy in different systems 
of traditional medicine have shown activity 
when tested in modern bioassays for the 
detection of anticonvulsant activity (Hedge et 
al., 2009). In this line, the present work was 
designed to investigate the anticonvulsant 
activity of extracts from six medicinal plants 
traditionally used to treat epilepsy in 
Cameroon. 
 
MATERIALS AND METHODS 
Plant collection 
The plant samples were collected in 
Yaoundé and its surroundings, Kon 
Yambettain the center region and Bafou in the 
western region of Cameroon during the month 
of August 2010. The plant species were 
identified at the Cameroon National 
Herbarium in Yaoundé where voucher 
specimens were deposited under the following 
identification numbers: 
Alchornea cordifolia (Euphorbiaceae): 4682/ 
SRFK 
Annona muricata (Annonaceae): 3289/HNC 
Annona senegalensis (Annonaceae): 40060/ 
HNC 
Desmodium adescendes (Fabaceae): 10258/ 
SRF/CAM 
Ficus thonningii (Moraceae): 44042/HCN 
Vitexdoniana (Verbenaceae): 21147/SRF/ 
CAM 
 
Plants extraction and dosage preparation 
Plants extraction 
Leaves, seeds, stems, stem barks, twigs, 
or whole plants were harvested, shade dried 
and ground using a laboratory blender.100 g 
of powdered materials of A. cordifolia leaves, 
A. senegalensis twigs and leaves, D. 
adescendes (whole plant), and V. doniana 
stem barks were individually macerated in 1L 
of MeOH/CH2Cl2 (1:1) at room temperature 
for 72 hours.100 g of A. muricata seed and 
stem and F. thoningii leaf and stem bark 
powders were similarly macerated in 1L of 
EtOH and water respectively. Upon 
maceration, filtrates were prepared using 
Whatman paper n°1. The aqueous filtrate was 
dried in an oven (Memmert) at 45 ºC for 
48hours. The organic solvents were 
evaporated under reduced pressure using a 
rotary evaporator (BÜCHI) at 40 °C then 65 
°C for the MeOH/CH2Cl2 (1:1) extract and at 
80 ºC for the ethanolic extract.  
 
Extracts dissolution and dosage preparation 
The extracts were diluted as needed for 
experiments each day. F. thonningii and V. 
doniana extracts were dissolved in water, 
while A. cordifolia and D. adescendes extracts 
were dissolved in DMSO/tween 20 and A.
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muricata and A. senegalensis were dissolved 
in olive oil. Extracts were tested at doses of 
1000, 700 and 500 mg/kg for D. adescendes 
and at 800, 400 and 200 mg/kg for A. 
muricata, A, senegalensis, F. thonningii and 
V. doniana. The convulsion inducer, 
Pentylenetetrazole (PTZ) and the positive 
control, Phenobarbital (PHB) were purchased 
from Sigma Chemical. They were dissolved in 
normal saline. PTZ was prepared freshly for 
each experiment and administered intraperiton 
eally (ip) in a volume of 10 ml/kg body 
weight. Control animals received the same 
volume of vehicle. 
 
Animals 
Healthy male and female Balb/c mice 
(Mus musculus) of 6 to 8 weeks, weighing 20 
to 24 g were used. They were housed at the 
animal house of the Faculty of Medicine and 
Biomedical Science of the University of 
Yaoundé 1 (Cameroon). Animals were 
separated into groups of 6 mice for 
experimentation and were maintained under 
standard conditions with free access to food 
and water ad libitum. All animals were fasted 
for 16 h, but still allowed free access to water 
prior to experiments. Laboratory animal care 
and experimentation were performed under 
protocols approved by the animal care and use 
committee of the National Institute of 
Neurological Disorders and Stroke (NINDS) 
in strict compliance with the Guide for the 
care and use of laboratory animals of the 
National Research Council (National 
Research Council, 1996, National Academy 
Press, Washington, DC). 
 
Evaluation of the anticonvulsant activity 
A total of 31 experimental groups of 6 
mice each were used for anticonvulsant 
evaluation using the method of Hosseinzadeh 





All the results obtained were expressed 
as mean ± standard deviation and were 
subjected to analysis of variance (ANOVA), 
and post hoc significance testing with Tukey’s 
multiple comparison test using Graph pad 5.0 
software. Significance was tested at 0.05. 
 
RESULTS 
The results obtained from this study are 
presented and discussed below. The 
parameters recorded after administration of 
plant extracts and PTZ to mice at the dose of 
90 mg/kg are summarized in Table 1. 
From Table 1, it appears that A. 
cordifolia leaf extract at up to 1000 mg/kg did 
not significantly modify (P> 0.05) the time to 
seizure onset, nor the appearance of 
tonicoclonic (TC) convulsions; but the 
duration of convulsions was significantly 
reduced (P<0.05) at all doses compared to 
PTZ. All animals were protected from death at 
the dose of 1000 mg/kg, 50% of mice were 
protected from death at 700 mg/kg. 
A. muricata stem extract at 200 and 400 
mg/kg was able to delay seizures induced by 
PTZ in a significant manner (P<0.05), while 
the onset of TC seizures was significantly 
delayed (P<0.05) at the highest dose tested for 
seeds (800 mg/kg) and the smallest for stem 
(200 mg/kg). All doses of these extracts 
significantly reduced (P<0.05) seizure 
duration and an entire protection was 
observed for the stem and seed extracts at 200 
mg/kg.  
Twig and leaf extracts of A. 
senegalensis significantly delayed (P<0.05) 
seizure onset at 800 mg/kg while the seizure 
duration was significantly reduced (P<0.05) at 
all doses. None of these extracts significantly 
delayed (P>0.05) the time of onset of TC 
convulsions compared to the nontreated 
negative control, but they delayed the time of 
death. These extracts significantly delayed 
(P<0.05) the onset of seizure in a comparable 
manner to PHB at 10 and 20 mg/kg. 
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Death time (S) % 
Protection 
Extracts 
 500 59.67±7.84b 99.50±6.95b 50.83±7.65a 261,50±44.49 33.33 
AlCl 700 57.67±4.13b 143.20±59.05b 98.00±8.78ab 682.67±6.4a 50 
 1000 67.17±11.83b 155.20±21.99b 73.83±9.94ab / 100 
 200 70.50±6.95b 124.00±11.46b 56.83±5.23a / 100 
AnMs 400 84.33±42.22b 94.00±1.41b 93.00±20.73ab 186.67±12.22a 50 
 800 71.50±10.50b 360.50±0.70ab 72.00±10.13ab 107.33±24.82a 50 
 200 132.67±10.05a 280.00±14.14ab 52.33±6.65a / 100 
AnMst 400 114.83±5.70a 229.33±31.00b 50.00±7.04a / 100 
 800 71.50±8.52b 146.00±1.41b 60.67±6.56a 917±4.24a 66.66 
 200 69.83±10.06b 155.67±7.37b 46.00±7.7a / 100 
AnStw 400 69.17±9.49b 111.00±11.40b 49.50±9.64a / 100 
 800 89.00±19.75ab 186±81.34b 48.17±5.26a 183 83.33 
 200 62.50±3.01b 98.50±7.32b 80.20±16.75ab / 100 
AnSl 400 61.50±3.01b 126.00±1.82b 55.00±8.57a / 100 
 800 102.50±12.19ab 209.00±4.96b 106.20±4.43ab / 100 
 500 63.33±3.67b 133.40±5.85b 65.40±5.03a / 100 
DeA 700 67.00±8.73b 64.00±18.60ab 59.40±26.86a / 100 
 1000 72.57±9.48b 83.60±18.87ab 72.60±9.15ab 503 83.3 
 200 74.25±4.34b 81.00±9.89b 146.00±13.92ab / 100 
FiTsb 400 83.25±15.88b 132.25±63.20b 48.75±8.53a / 100 
 800 64.29±20.62b 165.33±15.34b 97.00±19.59ab 207.50±57.27a 66.66 
 200 104.00±40.75ab 257.00±74.57ab 120.00±7.87ab 302.50±57.27 66.66 
FiTl 400 98.00±25.80ab 286.00±8.18ab 47.25±9.25a / 100 
 800 84.83±19.40b 298.05±4.14ab 84.75±18.99ab / 100 
 200 76.50±11.84b 121.75±39.30b 64.45±0.50a 328.00±15.68 33.33 
ViDsb 400 92.17±33.30ab 73.00±8.60ab 96.20±20.31a 343.25±56.64 33.33 
 800 129.17±10.76ab 77.50±10.40ab 89.50±9.53a 395.75±85.45 33.33 
Controls 
PHB 10 58.29±1.11b 1468.0±10.08b 64.43±0.78a 560.29±3.81a 0 
(ref 20 67.00±3.57b / 57.83±0.753a 1474.00±1.41a 66.66 
drug) 40 194.86±2.67a / 43.00±2.16a / 100 
PTZ 90 46.13±6.19b 172.25±49.22b 232.00±33.96 374.63±39.46 0 
Experimental data obtained are presented as means±SEM. /: animals were protected from the observed phenomenom; AlCl: 
Al. cordifolia leave, AnMs: A. muricata seed, AnMst: A. muricatastem, AnSl: A. senegalensis leave, AnStw: A. senegalensis 
twig, DeA: D. Adescendes, FiTsb: F. thoningii stem bark, FiTl: F. thoningii leave, ViDsb: V. doniana stem bark, PHB: 
phenobarbital, PTZ: pentylenetetrazol, the chemical convulsant; (S): seconds; a: significant compared to PTZ; b: significant 
compared to PHB. The significativity was observed at P<0.05. 
 
D. adescendens, at doses of 500, 700 
and 1000 mg/kg, significantly protected 
(P<0.05) mice from death, but was ineffective 
in delaying either the seizure onset or that of 
the TC convulsions. 
Leaf and stem bark extracts of F. 
thonningii significantly delayed (P<0.05) the 
seizure onset and the appearance of TC 
convulsions at 200 mg/kg. 
The bark extract of V. doniana 
significantly delayed (P<0.05) the seizure 
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onset at all doses tested. Convulsion duration 
was significantly reduced compared to the 
nontreated negative control. Besides, the 
activity of this extract at 200 mg/kg was 
similar to that of PHB at 10 mg/kg. All tested 
doses exhibited comparable levels of 
protection (33.33%), but lower than that of the 
treated positive control; PHB with 66 
and100% at 20 and 40mg/kg respectively. 
All the tested extracts significantly 
reduced (P<0.05) the convulsion duration 
compared to negative control. F. thonningii 
leaves and stem bark (800 mg/kg, 200 mg/kg), 
D. adescendes at 1000 mg/kg, A. senegalensis 
leaves (800 mg/kg, 200 mg/kg) and A. 
cordifolia (700 mg/kg, 1000 mg/kg) presented 
values far greater than that of the positive 
control group treated with the reference drug, 
phenobarbital (PHB).  
 
DISCUSSION 
Epilepsy is a common neurological 
condition associated with an alteration in 
psychological, emotional and educational 
parameters (Aldarmaa et al., 2010). 
Prevention of PTZ induced seizures in 
laboratory animals is the most commonly used 
initial screening test for discovery of 
anticonvulsant drugs. It is mostly believed that 
inhibitors exert the iraction by acting as 
antagonists at the picrotoxinin-sensitive site at 
the γ-aminobutyric acid (GABAA) receptor 
complex (Hansen et al., 2004). Accordingly, 
Huang et al. (2001) indicated that PTZ 
interacts with overlapping but distinct 
domains of the GABAA receptor. Within 2-4 
seconds of PTZ administration, there is an 
increase in blood oxygen levels. This increase 
was observed at the thalamus, especially the 
anterior thalamic nuclei. The peak of this 
activity which is twofold greater than in all 
other thalamic areas is reached few seconds 
before the first seizure (Brevard et al., 2006).  
Extracts from F. thonningii, a plant of 
the Moraceae family presented a significant 
anticonvulsant effect against PTZ-induced 
convulsion. No previous scientific study had 
ever revealed its anticonvulsant activity but 
however, Noumi and Fozi (2003) reported the 
use of a related plant (Ficus sycomorus) in 
combination with other plants such as 
Asystasia gangetica, Ficus mucoso, and 
Aframamum melegueta in Fongo-Tongo 
community in Cameroon to cure epileptsy. 
Beside this report, Tanzanian healers have 
been reported to boil the bark of Ficus 
sycomorus in the treatment of epilepsy (Moshi 
et al., 2005). Another study conducted by 
Sandabe et al. (2003) revealed that aqueous 
extract of F. sycomorus tem bark at the doses 
of 200 and 400 mg/kg protected laboratory 
animals from death while Ibrahim et al., 
(2008), using the flavonoid fraction of F. 
sycomorus, obtained an anticonvulsant 
activity against the PTZ and maximal 
electroshock seizure (MES) models at 10 
mg/kg. Singh and Goel (2009), working on 
another species of the same genus, Ficus 
religiosa, observed that the methanolic extract 
of figs at the maximum dose tested (100 
mg/kg) was not effective against the PTZ 
model but was able to protect animal from 
MES seizure starting at 25 mg/kg, the smallest 
dose tested. Similarly, the saponin fraction of 
the same plant at 1 mg/kg was able to 
decrease PTZ-induced seizures (Singh et al., 
2013). Another species, Ficus platyphylla, 
studied by Chindo et al. (2009) revealed that 
saponins extracted from the stem bark, tested 
at the minimal dose (25 mg/kg) were effective 
against in vivo and in vitro models of epilepsy.  
In our study, leaves and stem bark of F. 
thonningii at 200 mg/kg, the smallest dose 
tested, significantly delayed the onset of 
seizures in general and tonicoclonic seizures 
in particular. At this dose, the stem bark 
extract entirely protected the animals, while 
66.66% of mice were protected by leaf 
extract. 
An ethnobotanical survey of epilepsy 
treatment in Fongo-Tongo village, Western 
region of Cameroon by Noumi and Fozi 
(2003), revealed the use of D. adescendes 
leaves, V. doniana and A. senegalensis tem 
bark as drugs against epilepsy. They were 
effective when given to some epileptics who 
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claimed to be cured after an average period of 
18 months. The ethanolic extract of D. 
adescendes tested at 300 mg/kg, was effective 
against clonic convulsions induced by PTZ as 
reported by N’gouemo et al. (1997). In our 
study, the ethanolic extract of D. adescendes 
was able to protect mice from death at all 
doses tested, but was neither effective against 
seizure onset nor tonicoclonic seizures. 
Concerning A. senegalensis, Konate et al. 
(2012) reported the anticonvulsant property of 
the methanolic extract and aqueous fraction of 
the stem bark of A. senegalensis at 400 mg/kg. 
This result is different from what we obtained 
at the same dose and could be explained by 
the plant part used in our study or extraction 
solvent used. However, the activity observed 
at 800 mg/kg, particularly the onset seizure in 
our study confirmed the anticonvulsant 
property of this plant which did reduce the 
convulsion duration at all doses tested. 
A. muricata stem extract at 200 and 400 
mg/kg significantly delayed seizures, while 
the onset of TC seizures was significantly 
delayed at 200 and 800 mg/kg for the stem 
and seeds respectively. Our findings are 
similar to those obtained by N’gouemo et al. 
(1997) with the ethanolic extract of leaves of 
this plant at the dose of 300 mg/kg. Twigs and 
seeds significantly reduced seizure duration 
and conveyed entire protection at 200 mg/kg 
body weight in mice.  
A. cordifolia leaves did not 
significantly modify the time to seizure onset, 
nor the onset of tonicoclonic (TC) 
convulsions, but significantly reduced the 
duration of convulsions. In the contrary 
Pedersen et al. (2009) in a previuous study 
showed inhibition of spontaneous epileptic 
form discharges by the ethanolic extract of A. 
cordifolia leaves from Mali. This difference 
could be due to the difference in solvents 
used, or in the in vitro model compared to the 
in vivo approach used in our study. In fact, the 
in vitro active compounds could have been 
metabolized to non-active derivatives in the 
animal’s organism or did not cross the blood 
brain barrier. Otherwise, the active 
compounds present in the extract do not show 
effect on the PTZ model (Pedersen et al., 
2009).  
A comparison between the different 
extracts, show that the extract A. Muricata 
stem bark at 200 and 400 mg/kg, A. 
senegalensis stem bark and leaves at 800 
mg/kg, F. thonningii leaves at 200 and 400 
mg/kg and V. doniana at 400 and 800 mg/kg 
were able to delay seizure onset with the best 
activity observed for the A. muricata stem 
bark extract.  
The protection offered by plant extracts 
might be dependent upon synergistic effects 
of constituents. Indeed, phytochemical 
analysis of organs of these plants revealed the 
presence of alkaloids, saponins, tanins, 
anthraquinones, terpenoids, and flavonoids in 
the ethanolic and aqueous leaf extracts of V. 
doniana (Agbafor and Nwachukwu, 2011). 
Ayodele et al., (2007) working on the 
ethanolic extract of the leaves of A. cordifolia, 
found alkaloids, tannins, saponins, flavonoids 
and steroidal ring. The authors also stated a 
relationship between A. cordifolia intake and 
the prevention of neurodegenerative disease. 
A literature review, conducted by Rastogi et 
al. (2011), revealed that D. adscendens 
contains triterpenoids, saponins, 
tetrahydroisoquinolones, phenyle thylamines 
and indole-3-alkyl amines isolated from the 
leaves. Three active components were 
identified as the known triterpenoid 
glycosides dehydrosoya saponin I (DHS-I), 
soya saponin I and soya saponin III. 
Dehydrosoya saponin, the major saponin 
compound of the plant was the most potent 
potassium channel opener. As in the case with 
plants of the Annonaceae family, tannins, 
steroids and cardiac glycosides were the major 
compounds found in A. muricata 
(Gajalakshmi et al., 2012), while Arthur et al. 
(2011) working with the leaf aqueous extract 
of A. muricata found that saponins and 
flavonoids are also present in the plant. 
Another report by Boyom et al. (1996) 
revealed the presence of sesquiterpernes, 
particularly β- caryophyllene. As concerns A. 
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senegalensis, alkaloids, terpenoids, 
particularly monoterpenes were reported by 
Boyom et al. (1996). Saponins, another 
compound present in A. senegalensis was 
found in the aqueous extract of root bark 
(Konate et al., 2012). Added to this, resins, 
alkaloids, proteins, anthraquinones, sterols, 
glycosides and terpenes were also present in 
A. senegalensis (Adzu et al., 2005).  
Some extracts showed no effects in our 
study despite traditional claims, particularly 
concerning the onset of seizures, but they 
were all able to reduce the convulsion 
duration. Differences in metabolism between 
rodents and humans might explain such 
differences and justify the use in traditional 
medicine despite the lack of effect in the 
animal model (Pedersen et al., 2009). 
As far as the mechanism of action are 
concerned, the extract either increases the 
threshold of PTZ- induced convulsion or 
protects mice against convulsions induced by 
PTZ. Clonic seizures induced by PTZ are 
blocked by drugs that reduce T-type calcium 
currents and drugs that enhance inhibitory 
neuro-transmission by GABAA receptors 
(benzodiazepine, phenobarbital and valproate) 
(Chindo et al., 2009). The fact that the extracts 
protected animal against PTZ-induced 
seizures may suggest that they contain 
compounds that facilitate GABAergic 
transmission (Ayanniyi and Wannang, 2008).  
Despite the diversity of models that 
could potentially be used to screen for 
anticonvulsant activity, PTZ-induced acute 
seizures remains ‘Gold standard’ in the early 
stages of testing. The PTZ model is assumed 
to identify anticonvulsant drugs effective 
against petit mal seizures. The effects of 
extracts against PTZ-induced seizures thus 
suggest anticonvulsant efficacy against petit 
mal epilepsy in man (Chindo et al., 2009). 
 
Conclusion 
The pharmacological screening of the 
extracts of Cameroonian plants traditionally 
used against epilepsy, led to the identification 
of several extracts with potential 
anticonvulsant properties. However further 
investigation using other models of epilepsy 
are required to characterize their 
anticonvulsant and antiepileptic effects. 
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